ArticleTranslational vision science & technology2025
SS-OCT/OCTA Assessment of Choroidal Structure in Vitreoretinal Lymphoma Patients and Their Changes During Intravitreal Methotrexate Chemotherapy.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate choroidal structure changes in vitreoretinal lymphoma (VRL) patients during intravitreal methotrexate (MTX) therapy and quantitative characteristics of active VRL at choroidal level using swept-source optical coherence tomography angiography (SS-OCT/OCTA). Methods: In this retrospective study, patients diagnosed with VRL and received intravitreal MTX chemotherapy from January 2022 to December 2023 were included, along with healthy volunteers of the same age range and sex ratio. Three-phase intravitreal MTX chemotherapy consisting of induction, consolidation, and maintenance was scheduled. SS-OCT/OCTA images obtained before intraocular chemotherapy and by the end of each phase of treatment were reviewed. Choroidal thickness (CT), choriocapillaris (CC) perfusion area, choroidal vessel volume (CVV), choroidal vascularity index (CVI), and choroidal stromal volume (CSV) were analyzed. Results: Forty-four eyes of 29 VRL patients (15 males, 14 females) were enrolled in this study. CT, CVV, and CSV decreased significantly by the end of induction phase and maintained a continuous decrease during intravitreal MTX chemotherapy (all P < 0.05), whereas CC perfusion area and CVI remained statistically comparable. Comparative analysis demonstrated significantly lower CVI in VRL eyes versus normal controls across all measured regions (all P < 0.05), whereas CT, CVV, and CSV showed no intergroup differences. Conclusions: VRL eyes demonstrated a decreased CVI, which reflected lymphoma-induced structural changes at the choroidal level. After intravitreal MTX treatment, CT, CVV, and CSV all showed a significant reduction. Translational Relevance: SS-OCT/OCTA-derived choroidal parameters (CT, CC perfusion area, CVI, CVV, and CSV) enable noninvasive monitoring of choroidal changes in VRL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.